At the time of writing, Arcutis Biotherapeutics Inc [ARQT] stock is trading at $15.41, up 1.12%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ARQT shares have gain 6.06% over the last week, with a monthly amount drifted -4.64%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Arcutis Biotherapeutics Inc [NASDAQ: ARQT] stock has seen the most recent analyst activity on December 30, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $19. Previously, Jefferies started tracking the stock with Buy rating on August 28, 2024, and set its price target to $15. On January 03, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $8 on the stock. Mizuho downgraded its rating to a Neutral and decreased its price target to $4 on October 26, 2023. Goldman downgraded its rating to a Neutral and reduced its price target to $6 on October 13, 2023. Needham started tracking with a Buy rating for this stock on September 07, 2022, and assigned it a price target of $46. In a note dated March 17, 2022, Goldman initiated an Buy rating and provided a target price of $45 on this stock.
For the past year, the stock price of Arcutis Biotherapeutics Inc fluctuated between $6.99 and $17.75. Currently, Wall Street analysts expect the stock to reach $19 within the next 12 months. Arcutis Biotherapeutics Inc [NASDAQ: ARQT] shares were valued at $15.41 at the most recent close of the market. An investor can expect a potential return of 23.3% based on the average ARQT price forecast.
Analyzing the ARQT fundamentals
According to Arcutis Biotherapeutics Inc [NASDAQ:ARQT], the company’s sales were 196.54M for trailing twelve months, which represents an 427.58% jump. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -0.65%, Pretax Profit Margin comes in at -0.71%, and Net Profit Margin reading is -0.71%. To continue investigating profitability, this company’s Return on Assets is posted at -0.4, Equity is -0.77 and Total Capital is -0.48. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.7.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 15.06 points at the first support level, and at 14.72 for the second support level. However, for the 1st resistance point, the stock is sitting at 15.71, and for the 2nd resistance point, it is at 16.02.
Ratios To Look Out For
It is important to note that Arcutis Biotherapeutics Inc [NASDAQ:ARQT] has a current ratio of 4.15. Further, the Quick Ratio stands at 3.97, while the Cash Ratio is 0.88. Considering the valuation of this stock, the price to sales ratio is 9.35, the price to book ratio is 11.53.
Transactions by insiders
Recent insider trading involved Matsuda Masaru, that happened on May 02 ’25 when 5030.0 shares were sold., Watanabe Todd Franklin completed a deal on May 02 ’25 to sell 11448.0 shares. Meanwhile, Burnett Patrick sold 2597.0 shares on May 02 ’25.
